Scalper1 News
Big-cap biotech Celgene (CELG) said late Monday that it’s investing more than $1 billion in a partnership with startup Juno Therapeutics (JUNO), sending the latter’s stock soaring 35% in after-hours trading. Celgene will buy 9.1 million Juno shares for $1 billion and has the option to buy up to 30% of Juno’s total stock over the course of the 10-year collaboration. It will also make an upfront payment of $150 million in cash. Celgene will be Scalper1 News
Scalper1 News